This focused issue on “Neoadjuvant/Adjuvant Treatment For Early Breast Cancer” is edited by Dr. Yutaka Yamamoto, from Department of Breast and Endocrine Surgery, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan; and Takayuki Ueno, from Breast Oncology Center, Breast Surgical Oncology, Cancer Institute Hospital, Japan.
Dr. Yutaka Yamamoto is currently the Chief at the Department of Breast and Endocrine Surgery, Kumamoto University Hospital and the Associate Professor at the Department of Breast and Endocrine Surgery, Kumamoto University Graduate School of Medical Sciences. After residency program, he pursued a career in the field of translational research and clinical study in breast cancer. He has published over 100 peer-reviewed papers focusing on the biology, prognostic/predictive markers, imaging diagnosis and treatment for breast cancer. He also has conducted several clinical trials for breast cancer including randomized phase III trials. He is now an executive board member of the Japan Breast Cancer Society and the Japan Breast Cancer Research Group.
Dr. Takayuki Ueno is the director of the Department of Breast Surgical Oncology in Cancer Institute Hospital of JFCR, Tokyo. He graduated from the University of Tokyo and received M.D. in 1992. He trained as a physician for two years in the Hospital of the University of Tokyo and, thereafter, as a surgical oncologist in Tokyo Metropolitan Komagome Hospital. He started basic research on hormone receptor in 1998 in Saitama Cancer Center and continued oncology research in Karolinska Institute in Sweden. He got a Ph.D. in Karolinska Institute in 2004 with a research on suppression of cancer progression by an RGD-containing protease. In the meantime, he also worked on processing of pulmonary surfactant protein by the RGD-containing protease. As a surgical oncologist, he worked in Kyoto University and Kyorin University to study serum and tissue biomarkers. He is also working on translational research in Japan Breast Cancer Research Group (JBCRG) and Organisation for Oncology and Translational Research (OOTR). In 2017, he has moved to Cancer Institute Hospital, Tokyo, as director of the Department of Breast Surgical Oncology and studies liquid biopsy and cellular and molecular biology of cancer.
Focused issue outline:
- Introduction to this focused issue
- Concept of neoadjuvant/adjuvant treatemet for early breast cancer
- Neoadjuvant treatment for HER2-positive breast cancer
- Adjuvant treatment for HER2-positive breast cancer (including response-guide anti-HER2 treatment)
- Biomarkers of neoadjuvant/adjuvant treatment for HER2-positive breast cancer
- Neoadjuvant chemotherapy for HER2-negative breast cancer
- Adjuvant chemotherapy for HER2-negative breast cancer (including response-guide treatment)
- Biomarkers of neoadjuvant/adjuvant chemotherapy for HER2-negative breast cancer
- Neoadjuvant endocrine therapy for ER-positive/HER2-negative breast cancer
- Adjuvant endocrine treatment for ER-positive/HER2-negative breast cancer
- Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer
- Diagnostic imagines for residual tumor after neoadjuvant treatment
- Local management after neoadjuvant treatment for breast cancer
- Prospect of immunotherapy in neoadjuvant/adjuvant treatment for primary breast cancer